Mounjaro Weight Loss
- All
- News
- Web Stories
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
How A YouTuber Lost 10 Kg With Mounjaro And What It Did To His Emotions: 'Life Was Flat'
A YouTuber shared that while he lost 10 kg with Mounjaro, he also felt deprived of emotions. Irrespective of the situation, he remained neutral
-
GLP-1 Users Often Restart Medication After Stopping, Finds Study; What Exactly Happens After Quitting?
The study found that a significant portion of patients who discontinued the drug actually went back to treatment within a year.
-
Can Weight-Loss Drugs Make You Fall Out Of Love? The Science Behind The Viral Ozempic Theory
As millions begin using weight-loss drugs, a new question is surfacing online and in medical discussions: could these medications also influence romantic desire or intimacy?
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Tanmay Bhat Says He Had No Hunger Suppression While On Weight Loss Drugs; Here's Why
While GLP-1 medications are highly effective for many, an estimated 13% to 25% of users may be considered non-responders who do not experience desired appetite suppression or weight loss.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Weight-Loss Surgery May Protect Your Heart More Than Drugs Like Ozempic, Mounjaro: Study
A new study suggests bariatric surgery may offer stronger long-term heart protection than GLP-1 drugs like Ozempic and Mounjaro.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
How A YouTuber Lost 10 Kg With Mounjaro And What It Did To His Emotions: 'Life Was Flat'
A YouTuber shared that while he lost 10 kg with Mounjaro, he also felt deprived of emotions. Irrespective of the situation, he remained neutral
-
GLP-1 Users Often Restart Medication After Stopping, Finds Study; What Exactly Happens After Quitting?
The study found that a significant portion of patients who discontinued the drug actually went back to treatment within a year.
-
Can Weight-Loss Drugs Make You Fall Out Of Love? The Science Behind The Viral Ozempic Theory
As millions begin using weight-loss drugs, a new question is surfacing online and in medical discussions: could these medications also influence romantic desire or intimacy?
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Tanmay Bhat Says He Had No Hunger Suppression While On Weight Loss Drugs; Here's Why
While GLP-1 medications are highly effective for many, an estimated 13% to 25% of users may be considered non-responders who do not experience desired appetite suppression or weight loss.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Weight-Loss Surgery May Protect Your Heart More Than Drugs Like Ozempic, Mounjaro: Study
A new study suggests bariatric surgery may offer stronger long-term heart protection than GLP-1 drugs like Ozempic and Mounjaro.
-
Novo Nordisk's CagriSema Delivers 23% Weight Loss In Trial But Still Trails Eli Lilly's Tirzepatide
CagriSema is a once-weekly subcutaneous injection, which is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity.
